On February 29 at 1pm PT, the Lewy Body Dementia Association (LBDA) will host a webinar on “Introduction to Synuclein Biomarkers: How Researchers are ‘Seeing’ Lewy Bodies in the Living Brain.” Kathleen Poston, MD, will discuss recent advances in the development of biomarkers for alpha-synuclein, how they are changing research in Lewy body dementia (LBD), and how they may change clinical practice in the future.

Currently, diagnosis of LBD is made based on signs and symptoms reported and observed during visits with your doctor. This practice is the basis of the term ‘clinical diagnosis.’ One of the primary challenges to clinical diagnosis has been that there was no laboratory test that could tell during life who had the hallmark brain change associated with LBD. In recent years, though, tremendous progress has been made in developing such tests – which researchers call biomarkers.

Register here for the webinar, Introduction to Synuclein Biomarkers: How researchers are “seeing” Lewy bodies in the living brain on Feb. 29 at 1pm PT to learn more.

During this webinar, Dr. Kathleen Poston, a leading figure in LBD research and care and co-lead of the LBDA Research Center of Excellence at Stanford University will spell out some of the basics about diagnosing LBD and biomarkers, including:

• The current diagnostic process for LBD
• What is a biomarker
• The ways in which medical professionals may test a person for the presence of Lewy bodies in the brain
• Why your doctor may or may not prescribe a test

Can’t make it? Register anyway, and LBDA will notify you when the recording is available on LBDAtv, and share details about upcoming webinars.